Sync Biosystems secures €2.5M to validate technology with international end users

The international δypha Consortium has received a European Innovation Council Transition grant of 2.5 million euros for bringing Sync Biosystems’ technology from pilot to product. Industrial and research leaders, integral members of the consortium, participate as end users: Charles River Laboratories, Princess Máxima Center for Pediatric Oncology and Bambino Gesù Children’s Hospital. With dedicated showcases, they will demonstrate how the technology impacts their drug development assays and their search for better therapies for patients. To translate the results from the in vitro technology to patient-relevant levels, consortium partner ESQlabs will develop specific physiologically-based computational models. The goal of δypha is to improve cell culture and drug testing with automated and continuous fluidic control in standard cell culture plates. Read more

Share This Story, Choose Your Platform!



Producten & werkwijze